Clinical impact of a change in antibiotics or the addition of glycopeptide antibiotics for persistent febrile neutropenia after autologous stem cell transplantation.

autologous hematopoietic stem cell transplantation changes in antibiotics febrile neutropenia glycopeptide antibiotics

Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
24 Jun 2024
Historique:
received: 30 04 2024
revised: 04 06 2024
accepted: 21 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 26 6 2024
Statut: aheadofprint

Résumé

A change in empirical antibiotics or the addition of glycopeptide antibiotics is often applied in cases of persistent febrile neutropenia (FN) despite the administration of broad-spectrum antibiotics. However, the clinical benefit of these approaches remains unclear. We conducted a retrospective study to evaluate the effectiveness of a change in antibiotics or the addition of glycopeptide antibiotics for persistent FN after autologous hematopoietic cell transplantation (auto-HCT). We retrospectively reviewed the records of 208 patients who received auto-HCT at our institution between 2007 and 2019. FN that lasted for 4 days or longer was defined as persistent FN. We compared the time to defervescence between patients whose initial antibiotics were changed and/or who additionally received glycopeptide antibiotics, and those without these antibiotic modifications. Among patients who fulfilled the criteria of persistent FN (n = 125), changes in antibiotics were not significantly associated with the time to defervescence in a multivariate analysis (hazard ratio [HR] 0.72, p = 0.27). On the other hand, the addition of glycopeptide antibiotics was paradoxically associated with a delay in defervescence (HR 0.56, p = 0.033). Although there may be differences in patient backgrounds, no significant differences were observed in either a univariate or multivariate analysis. Since neither a change in antibiotics nor the addition of glycopeptide antibiotics was associated with earlier defervescence in persistent FN after auto-HCT, routine antibiotic modifications might not be necessary in this setting.

Sections du résumé

BACKGROUND BACKGROUND
A change in empirical antibiotics or the addition of glycopeptide antibiotics is often applied in cases of persistent febrile neutropenia (FN) despite the administration of broad-spectrum antibiotics. However, the clinical benefit of these approaches remains unclear.
METHODS METHODS
We conducted a retrospective study to evaluate the effectiveness of a change in antibiotics or the addition of glycopeptide antibiotics for persistent FN after autologous hematopoietic cell transplantation (auto-HCT). We retrospectively reviewed the records of 208 patients who received auto-HCT at our institution between 2007 and 2019. FN that lasted for 4 days or longer was defined as persistent FN. We compared the time to defervescence between patients whose initial antibiotics were changed and/or who additionally received glycopeptide antibiotics, and those without these antibiotic modifications.
RESULTS RESULTS
Among patients who fulfilled the criteria of persistent FN (n = 125), changes in antibiotics were not significantly associated with the time to defervescence in a multivariate analysis (hazard ratio [HR] 0.72, p = 0.27). On the other hand, the addition of glycopeptide antibiotics was paradoxically associated with a delay in defervescence (HR 0.56, p = 0.033).
CONCLUSIONS CONCLUSIONS
Although there may be differences in patient backgrounds, no significant differences were observed in either a univariate or multivariate analysis. Since neither a change in antibiotics nor the addition of glycopeptide antibiotics was associated with earlier defervescence in persistent FN after auto-HCT, routine antibiotic modifications might not be necessary in this setting.

Identifiants

pubmed: 38925426
pii: S1341-321X(24)00173-9
doi: 10.1016/j.jiac.2024.06.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no potential conflicts of interest to disclose.

Auteurs

Nozomu Yoshino (N)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Shun-Ichi Kimura (SI)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Koji Kawamura (K)

Division of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.

Yuya Nakata (Y)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Akari Matsuoka (A)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Takuto Ishikawa (T)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Tomohiro Meno (T)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Yuhei Nakamura (Y)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Masakatsu Kawamura (M)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Shunto Kawamura (S)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Junko Takeshita (J)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Yukiko Misaki (Y)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Kazuki Yoshimura (K)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Ayumi Gomyo (A)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Yosuke Okada (Y)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Masaharu Tamaki (M)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Machiko Kusuda (M)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Kazuaki Kameda (K)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Yu Akahoshi (Y)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Miki Sato (M)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Aki Tanihara (A)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Hideki Nakasone (H)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Shinichi Kako (S)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Yoshinobu Kanda (Y)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan. Electronic address: ycanda-tky@umin.ac.jp.

Classifications MeSH